A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

A family history of prostate cancer has long been one of the few universally accepted risk factors for the disease. New findings now provide evidence that risk stratification based on family history ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...

Please provide your email address to receive an email when new articles are posted on . Researchers developed a multi-ancestry polygenic score using data from two genome-wide association studies.

MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) ...

“What makes the score so powerful is its ability to predict, before the age of five, whether a child is likely to develop obesity in adulthood, well before other risk factors start to shape their ...

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...

Cancer is challenging to treat, yet identifying individuals with greater risk of developing disease can assist with early detection and increased treatment efficacy. There are several types of risk ...